L3VLUP
ProSign in

AMGN · RVMD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AMGNRVMD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AMGN
  • RVMD
0102030202120222023202420252026
Holders and value by quarter
QuarterAMGNRVMD
Q3 202016 holders, $16.3bn3 holders, $388m
Q4 202019 holders, $14.0bn4 holders, $451m
Q1 202116 holders, $14.5bn5 holders, $846m
Q2 202123 holders, $13.8bn5 holders, $325m
Q3 202124 holders, $11.6bn3 holders, $133m
Q4 202121 holders, $10.4bn3 holders, $174m
Q1 202223 holders, $9.9bn3 holders, $174m
Q2 202228 holders, $9.7bn3 holders, $189m
Q3 202221 holders, $7.9bn3 holders, $206m
Q4 202224 holders, $9.3bn3 holders, $263m
Q1 202322 holders, $8.4bn5 holders, $526m
Q2 202326 holders, $7.4bn7 holders, $685m
Q3 202326 holders, $8.7bn8 holders, $766m
Q4 202324 holders, $8.4bn8 holders, $1.0bn
Q1 202425 holders, $6.7bn10 holders, $1.3bn
Q2 202420 holders, $8.0bn9 holders, $1.6bn
Q3 202421 holders, $8.8bn10 holders, $1.9bn
Q4 202420 holders, $8.2bn11 holders, $2.2bn
Q1 202525 holders, $12.0bn7 holders, $1.7bn
Q2 202520 holders, $10.2bn8 holders, $1.7bn
Q3 202517 holders, $10.4bn7 holders, $2.2bn
Q4 202519 holders, $18.0bn18 holders, $4.3bn
Q1 202615 holders, $21.4bn15 holders, $4.8bn
Q2 202623 holders, $24.9bn17 holders, $10.3bn
AMGN

Amgen Inc

Holders
15
Reported value
$21.4bn
Buyers
17
Sellers
15

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
RVMD

Revolution Medicines Inc

Holders
15
Reported value
$4.8bn
Buyers
14
Sellers
20

Breadth -6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2026

Among the 25 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AMGN (10)

AllianceBernstein LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Dodge & Cox, Invesco Ltd, Marshall Wace LLP, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC

Only RVMD (10)

Baillie Gifford & Co, D. E. Shaw & Co., Davidson Kempner Capital Management LP, Farallon Capital Management LLC, Holocene Advisors LP, Moore Capital Management LP, Two Sigma Investments LP, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →